Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first patient dosing in its Phase 2a trial of PTX-100 for cutaneous T-cell lymphoma (CTCL), following the US FDA’s decision to grant the investigational cancer therapy Fast Track designation.
The designation provides access to expedited regulatory pathways in the US, recognising PTX-100’s potential to address an unmet need in relapsed or refractory mycosis fungoides, the most common CTCL subtype. Prescient closed the quarter with $6.9 million in cash and later raised a further $6.8 million via a Share Purchase Plan (SPP), which concluded in July.
PTX-100 gains momentum with Fast Track status and Phase 2a trial under way
The June quarter marked a major step forward for Prescient’s lead targeted therapy, PTX-100, with the FDA’s Fast Track designation unlocking benefits such as rolling New Drug Application (NDA) submissions and greater access to the agency during development.
Prescient followed up this regulatory milestone by initiating its Phase 2a clinical trial, designed to evaluate two dosage levels of PTX-100 in around 40 patients with relapsed or refractory CTCL. The open-label, randomised study is assessing efficacy as its primary endpoint, with safety among the secondary measures.
As of June 30, 2025, two Australian trial sites had been activated, with additional sites in Australia and the US expected to come online from July. Up to 16 sites are planned globally, including in Europe.
Cash flow and financing
Prescient ended the June quarter with $6.9 million in cash reserves, down from $10.2 million at the end of March. Net operating outflows totalled $3.3 million for the period, with $2.2 million directed towards research and development.
The $6.8 million SPP completed after the reporting period further strengthened the company’s financial position, providing additional runway to support ongoing clinical development of PTX-100. A follow-on placement to professional and sophisticated investors was also initiated under a trading halt on July 29.
Ongoing interest in PTCL and early-stage pipeline
While the focus remains on CTCL, Prescient is continuing to explore opportunities to gather more clinical data for PTX-100 in peripheral T-cell lymphoma (PTCL), another rare and aggressive cancer subtype.
The company also reported progress across its cell therapy platforms. CellPryme-M, a non-disruptive technology aimed at improving the function and durability of cell therapies, is now the subject of several external collaborations with potential partners. Updates on these programs will follow as they mature.
At the same time, technical work on the OmniCAR universal immune receptor platform has led to improved molecular variants and positive preclinical outcomes. Prescient expects development and validation work to continue as part of its broader immuno-oncology pipeline.
Board appointment adds sector experience
During the quarter, the company appointed Melanie Farris as an independent non-executive director. Farris brings experience from governance and leadership roles across Australian biotech companies, including Telix Pharmaceuticals Ltd and Invion Ltd, and now chairs Prescient’s audit and risk committee.
Prescient’s recent momentum in clinical development and regulatory recognition places it in a stronger position to pursue targeted cancer therapies for patients with limited treatment options. Further patient recruitment, trial site expansion and data generation are expected to be key areas of focus in the current quarter.